New Evidence Shows Morinaga Milk’s Probiotic Bifidobacterium breve A1 Improves Memory of Older Adults With Cognitive Dysfunction
Morinaga Milk Industry Co., Ltd. (TOKYO:2264), a leading Japanese dairy product company and a key global probiotics manufacturer, confirmed that its proprietary probiotic strain Bifidobacterium breve A1 (a.k.a. B. breve MCC1274) is safe and effective for improving memory functions of older adults with suspected mild cognitive impairment (MCI) in a randomized, double-blind, placebo-controlled trial (RCT).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200709005032/en/
Figure 1. Changes of RBANS scores at 16 weeks from baseline. Values are indicated as mean with error bars as the standard error. **p<0.001, ***p<0.0001, inter-group difference, Student’s t-test. (Graphic: Business Wire)
The new study, published recently in the Journal of Alzheimer’s Disease, has produced breakthrough results uncovering a novel promising probiotic intervention for early dementia prevention. The clinical study conducted by a clinical research organization, Huma R&D Co., Ltd. in Tokyo, Japan, in collaboration with Morinaga Milk Industry Co., Ltd, is the first RCT report to show a profound cognitive enhancement benefit of the probiotic B. breve A1 in subjects with suspected MCI.
“Our findings represent an important breakthrough for MCI and dementia prevention,” says Dr. Xiao, Director of Next Generation Science Institute of Morinaga Milk, and a principal investigator of the trial. “It marks major progress in our investigation on the ability of the probiotic strain B. breve A1 to halt the cognitive decline of older adults.”
Globally, the number of people living with dementia, including Alzheimer’s disease, will increase from 50 million in 2018 to 152 million in 2050, reaching epidemic proportions. According to the Alzheimer’s Association website, it is estimated that one new patient is diagnosed with Alzheimer’s disease every 65 seconds (https://www.alz.org/alzheimers-dementia/facts-figures), causing an unprecedented burden to society.
MCI is a common problem in older adults associated with the risk of developing sporadic Alzheimer’s disease or other dementia within a few years if left untreated. Currently, no medications have proven effective for MCI. Although several trials of pharmacological treatments were thought to prevent the symptoms of MCI, the results have been disappointing. Hence, there is an urgent need to identify effective countermeasures to MCI and dementia.
Previous studies by Morinaga Milk Industry Co., Ltd. have demonstrated the potential of B. breve A1 to treat Alzheimer’s disease in a pre-clinical model and found that this probiotic strain can improve specific cognitive functions in subjects with MCI in a human clinical trial. The current study conducted on 80 healthy older adults with suspected MCI further confirmed the efficacy of B. breve A1 on cognitive improvement.
Remarkable Improvement in RBANS Total Score
Participants randomly received either B. breve A1 or placebo by capsule for 16 weeks. At the end of the study, Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) total score showed a significant 11.3-point improvement in those taking A1 compared to placebo, in particular for domain scores of immediate memory, visuospatial/constructional, and delayed memory. In addition, significant improvement of cognitive function was confirmed by another test, the Japanese version of the MCI Screen.
Dr. Xiao said, “It was exciting to see a clear and significant improvement of memory functions such as the awareness of who, when, and where. The 11.3-point improvement of RBANS total score seen after only 16 weeks of daily consumption of the probiotic B. breve A1 in healthy older adults with MCI is remarkable.”
“Our findings could signal a profound shift as to how MCI can be treated using probiotics. Future discoveries for the precise mechanisms as to how daily consumption of B. breve A1 can improve memory will open new opportunities and alternatives for not only MCI treatment but perhaps also for other CNS diseases associated with inflammation and memory impairment.”
First Evidence of HRB Probiotics in Improving Cognitive Function of MCI and Supporting Healthy Cognitive Ageing
Pioneer in bifidobacteria research, Morinaga Milk has been focusing on the study of bifidobacteria species that are naturally present in human intestines – human-residential bifidobacteria (HRB) – for over 50 years and discovered various health benefits of its HRB strains. To continue exploring the potential of its HRB strains, in recent years, the company has focused on the gut-brain connection – a rapidly growing area of probiotics research – and conducted various research on cognitive improvement.
Embracing a significant milestone, Morinaga Milk is delighted to have uncovered the beneficial effects of its proprietary probiotic B. breve A1 on memory improvement. B. breve A1 originating from newborn infants’ intestines is the first human-residential bifidobacteria (HRB) strain that shows great promise to improve the memory of older adults with MCI and support healthy cognitive ageing.
“This breakthrough study is yet another indication of our continuous efforts to add value to our premium line of HRB probiotic strains,” said Ko Shiino, General Manager of Sales and Marketing Department, International Division of Morinaga Milk. “This promising finding will open up new business opportunities and is potentially game-changing. We are excited about the potential implications of B. breve A1 as a novel practical approach to promote healthy ageing.”
About Morinaga Milk
Morinaga Milk Industry Co., Ltd. is one of the leading dairy product companies in Japan with a century of history harnessing the nutritional properties of dairy products and its functional ingredients. Morinaga Milk excels in innovative technology and offers various dairy products and other beneficial functional ingredients to customers throughout the world. Since the 1960s, Morinaga Milk has been engaged in research on the safety, functional health benefits, and mechanisms of action of probiotic bifidobacteria to better understand their role in maintaining human health. For more information about Morinaga Bifidobacteria, please visit us at http://bb536.jp/english/index.html.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200709005032/en/
Contact information
Chyn Boon Wong
Morinaga Milk Industry Co., Ltd.
+81-3-3798-0152
chynboon020@morinagamilk.co.jp
http://www.morinagamilk.co.jp/english/
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Forge Biologics’ Novel AAV Gene Therapy FBX-101 for Patients with Krabbe Disease is Granted UK’s Innovation Passport Designation19.3.2024 15:00:00 EET | Press release
Forge Biologics, a member of Ajinomoto Bio-Pharma Services and a leading manufacturer of genetic medicines, today announced that the Medicines and Healthcare Products Regulatory Agency (MHRA), the healthcare regulatory body of the United Kingdom (UK), granted Innovation Passport designation to the Company’s novel AAV gene therapy program, FBX-101, to enter the Innovative Licensing and Access Pathway (ILAP). FBX-101 was created for the treatment of patients with Krabbe disease, a rare neurodegenerative disease that is usually fatal in untreated patients by age two. The ILAP is intended to accelerate regulatory and market access interactions in the UK. Maria Escolar, M.D., Forge’s Chief Medical Officer, will discuss the significance of achieving this regulatory designation and present a poster on updated data from REKLAIM, an early phase clinical trial for FBX-101, during the Advanced Therapies 2024 conference being held in London, March 19-20, 2024. “Considering the rapid progression of
SWISSto12 Continues Expansion, Growing Team by 25% and Adding New Production Space19.3.2024 15:00:00 EET | Press release
SWISSto12, one of Europe’s fastest growing aerospace companies and a leading satellite and Radio Frequency product manufacturer, announces its continued global expansion. The company has secured additional production space at its headquarters in Switzerland, increasing the size of its existing site to 5,700m2. In addition, SWISSto12 has welcomed several new Satcom engineering experts to its growing team, which has increased by 25% since the start of 2024 to over 125 employees working across its facilities in Switzerland, Europe and the USA. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240318493042/en/ HummingSat I-8 Inmarsat (Photo: Business Wire) SWISSto12 was recently named as one of the world’s “10 Hottest Satellite Companies.” This industry recognition follows the company’s announcement in Q4 2023 of securing over €200 million in customer orders for Radio Frequency subsystems and HummingSat satellites, including from l
Mainstay Medical Announces Publication of the First Neuromodulation Study for Low Back Pain with 5-Year Follow-Up19.3.2024 15:00:00 EET | Press release
Mainstay Medical Holdings plc today announced the publication of the 5-year follow up from the ReActiv8-B randomized, sham-controlled, double-blinded trial. There were 126 patients who completed the 5-year follow up, and the published data clearly indicated that ReActiv8® Restorative Neurostimulation is a long-term, effective, durable, and safe therapy. ReActiv8 is the only restorative therapy for patients suffering from non-surgical, mechanical CLBP evidenced by multifidus dysfunction. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240319164677/en/ The long-term responses across pain, disability, and health-related quality of life measures are shown in the following graphs. (Graphic: Business Wire) The publication is available here: https://www.sciencedirect.com/science/article/pii/S1094715924000552 The ReActiv8-B study saw multiple patients have their implants removed for resolution of back pain. These removals for success
AngloGold Ashanti Releases Preliminary Unaudited Condensed Consolidated Financial Statements as of and for the Six Months and the Year Ended 31 December 202319.3.2024 14:04:00 EET | Press release
AngloGold Ashanti plc (“AngloGold Ashanti”, “AGA” or the “Company”) is pleased to provide its preliminary unaudited condensed consolidated financial statements as of and for the six months and the year ended 31 December 2023 (the “FY 2023 Earnings Release”). FY 2023 Financial and Operating Update The FY 2023 Earnings Release should be read together with AngloGold Ashanti’s preliminary financial update for the six months and the year ended 31 December 2023, which was published by the Company on 23 February 2024 (the “FY 2023 Preliminary Financial Update”). No changes have been made in the FY 2023 Earnings Release with respect to the production, cost or cash flow information included in the FY 2023 Preliminary Financial Update. The FY 2023 Preliminary Financial Update combined with the FY 2023 Earnings Release provide the Company’s financial and operating update for the six months and the year ended 31 December 2023. Announcement of Annual General Meeting Date The 2024 Annual General Mee
IFF Announces Sale of its Pharma Solutions Business to Roquette19.3.2024 13:45:00 EET | Press release
IFF (NYSE: IFF) today announced that it has entered into a definitive agreement to sell its Pharma Solutions business unit to French leader of plant-based ingredients Roquette for an enterprise value of up to $2.85 billion, which represents an enterprise value to EBITDA multiple of approximately 13x. IFF’s Pharma Solutions business is a well-established developer and manufacturer of pharmaceutical excipients and includes its Global Specialty Solutions business supporting industrial and methyl cellulosic food applications. The Pharma Solutions business being sold to Roquette is primarily made up of businesses within IFF’s existing Pharma Solutions division, with some adjustments to the perimeter of the transaction designed to align customers, businesses and the manufacturing footprint. “We are pleased to reach an agreement with Roquette that will support Pharma Solutions’ next chapter of growth as a trusted partner for the pharmaceutical industry,” said IFF CEO Erik Fyrwald. "An importa
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom